clodronate + tamoxifen

Clodronate + tamoxifen is a combination therapy consisting of two small molecule drugs used primarily in the context of breast cancer treatment and research. Clodronate is a bisphosphonate that inhibits bone resorption by osteoclasts, thereby reducing skeletal-related events such as fractures and bone metastases. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as an antagonist to estrogen receptors in breast tissue, inhibiting the growth of estrogen receptor-positive (ER+) breast cancer cells. The rationale for combining these agents lies in their complementary mechanisms—tamoxifen targets tumor proliferation via hormonal pathways, while clodronate addresses bone complications often associated with metastatic breast cancer. This combination has been studied for its potential to improve outcomes in patients with ER+ breast cancer, particularly those at risk for or experiencing bone metastases[1][3][5].